Identification and Targeting of Metastasis-Suppressing miRNAs in Triple-Negative Breast Cancer
Technical Report,15 Apr 2016,14 Apr 2019
Joan and Sanford I. Weill Medical College New York United States
Pagination or Media Count:
Triple-negative breast cancer TNBC constitutes 20-25 of all breast cancer cases and has the worst prognosis due to high rates of distant recurrence, high rates of metastasis and a lack of effective molecularly targeted therapies. For patients diagnosed with advanced TNBC, the median duration of survival is only 12 months, which is much shorter than for patients diagnosed with other types of breast cancer. Therefore, TNBC patients, especially those presenting with advanced stage disease, are in desperate need of novel molecularly targeted therapies. Since TNBC is heterogeneous, the molecular underpinnings have been difficult to discern, thus making it challenging to develop effective targeted therapeutics. miRNA replacement therapy is a novel type of targeted therapy that is beginning to be investigated in clinical trials as it shows great promise. The remaining hurdle, however, is uncovering the most effective method for in vivo delivery. One mechanism for delivery that has not been previously investigated is a liposome-like structure called a DNA some, which is ideal for the in vivo delivery of small RNA molecules. We therefore hope to develop miRNA replacement therapy for the regression of existing metastases in late-stage TNBC patients using the DNA some.
- Medicine and Medical Research